Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study.
Fiche publication
Date publication
septembre 2021
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S
Lien Pubmed
Résumé
Fistulizing Crohn's disease (CD) is challenging to treat. We report results from ENTERPRISE, a randomized, double-blind, phase 4 trial, evaluating 2 vedolizumab intravenous dosing regimens in patients with fistulizing CD.
Mots clés
Crohn’s disease, fistula, fistulae closure, vedolizumab
Référence
Clin Gastroenterol Hepatol. 2021 Sep 28;: